Programme for the NMPN Spring Meeting 2019

Date: The 6th of March 2019, 10:00 – 17:10
Venue: Clarion Hotel Copenhagen Airport, Denmark

10:00 – 10:30: Registration and light morning meal

10:30 – 10:35: Welcome by chairman Christen Lykkegaard Andersen and secretary Trine Alma Knudsen

10:35 – 11:00: Myeloproliferative neoplasms and thromboembolic disease - just add aspirin? Christen Lykkegaard Andersen, MD, DMSc, PhD, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Denmark

11:00 – 11:15: Prevalence of calretikulin and JAK2V617F mutations in the general population, Sabrina Cordua, MD, PhD, Department of Haematology, Zealand University Hospital, Roskilde, Denmark

11:15 – 12:15: Keynote presentation
Molecular insights into JAK2 regulation in MPNs, Olli Silvennoinen, professor, MD, PhD, Director of Institute of Biotechnology, Helsinki, Finland

12:15 – 13:15: Lunch

13:15 – 14:15: Keynote presentation
Interferon in the treatment of MPNs, Heinz Gisslinger, professor, MD, Medical University of Vienna, Austria

14:15 – 14:45: The DALIAH trial, Trine Alma Knudsen, MD, Department of Haematology, Zealand University Hospital, Roskilde

14:45 – 15:15: Ruxolitinib and pegylated interferon-alpha2 combination therapy, Anders Lindholm Sørensen, MD, Institute for Inflammation Research, Rigshospitalet, Copenhagen University Hospital, Denmark

15:15 – 15:45: Afternoon Break
15:45 – 16:30: Therapeutic cancer vaccines in MPN – from bench to bedside, Morten Holmström, MD, PhD, National Center for Cancer Immunotherapy, Copenhagen University Hospital, Herlev, Denmark and Jacob Grauslund, MD, National Center for Cancer Immunotherapy, Copenhagen University Hospital, Herlev, Denmark

16:30 – 17:00: Eosinophilia, Christen Lykkegaard Andersen, MD, DMSc, PhD, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Denmark

17:00 – 17:10: Rounding off the day by chairman Christen Andersen and secretary Trine Alma Knudsen

18:00 – 22:00: 3-course dinner

The meeting is sponsored by Novartis and AOP Orphan Pharmaceuticals.